191 related articles for article (PubMed ID: 33744452)
1. Optimized semisolid self-nanoemulsifying system based on glyceryl behenate: A potential nanoplatform for enhancing antitumor activity of raloxifene hydrochloride in MCF-7 human breast cancer cells.
Badr-Eldin SM; Aldawsari HM; Ahmed OAA; Alhakamy NA; Neamatallah T; Okbazghi SZ; Fahmy UA
Int J Pharm; 2021 May; 600():120493. PubMed ID: 33744452
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
Jain A; Sharma T; Kumar R; Katare OP; Singh B
Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178
[TBL] [Abstract][Full Text] [Related]
3. Self-Assembling Raloxifene Loaded Mixed Micelles: Formulation Optimization, In Vitro Cytotoxicity and In Vivo Pharmacokinetics.
Kanade R; Boche M; Pokharkar V
AAPS PharmSciTech; 2018 Apr; 19(3):1105-1115. PubMed ID: 29181706
[TBL] [Abstract][Full Text] [Related]
4. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal.
Elsheikh MA; Elnaggar YS; Gohar EY; Abdallah OY
Int J Nanomedicine; 2012; 7():3787-802. PubMed ID: 22888234
[TBL] [Abstract][Full Text] [Related]
5. Lipidic Nano-Sized Emulsomes Potentiates the Cytotoxic and Apoptotic Effects of Raloxifene Hydrochloride in MCF-7 Human Breast Cancer Cells: Factorial Analysis and In Vitro Anti-Tumor Activity Assessment.
Aldawsari HM; Ahmed OAA; Alhakamy NA; Neamatallah T; Fahmy UA; Badr-Eldin SM
Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34073780
[TBL] [Abstract][Full Text] [Related]
6. In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance.
Ahmed OA; Badr-Eldin SM
Int J Nanomedicine; 2018; 13():6325-6335. PubMed ID: 30349253
[TBL] [Abstract][Full Text] [Related]
7. QbD-based optimization of raloxifene-loaded cubosomal formulation for transdemal delivery: ex vivo permeability and in vivo pharmacokinetic studies.
Gupta T; Kenjale P; Pokharkar V
Drug Deliv Transl Res; 2022 Dec; 12(12):2979-2992. PubMed ID: 35462597
[TBL] [Abstract][Full Text] [Related]
8. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
Saini D; Fazil M; Ali MM; Baboota S; Ali J
Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
[TBL] [Abstract][Full Text] [Related]
9. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.
Liu H; Lee ES; Gajdos C; Pearce ST; Chen B; Osipo C; Loweth J; McKian K; De Los Reyes A; Wing L; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1586-97. PubMed ID: 14600091
[TBL] [Abstract][Full Text] [Related]
10. Folic acid anchored urchin-like raloxifene nanoparticles for receptor targeting in breast cancer: Synthesis, optimisation and in vitro biological evaluation.
Sinai Kunde S; Wairkar S
Int J Pharm; 2022 Jul; 623():121926. PubMed ID: 35716974
[TBL] [Abstract][Full Text] [Related]
11. Ovariectomy-Induced Mitochondrial Oxidative Stress, Apoptosis, and Calcium Ion Influx Through TRPA1, TRPM2, and TRPV1 Are Prevented by 17β-Estradiol, Tamoxifen, and Raloxifene in the Hippocampus and Dorsal Root Ganglion of Rats.
Yazğan Y; Nazıroğlu M
Mol Neurobiol; 2017 Dec; 54(10):7620-7638. PubMed ID: 27832523
[TBL] [Abstract][Full Text] [Related]
12. Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study.
Shah N; Seth A; Balaraman R; Sailor G; Javia A; Gohil D
Drug Dev Ind Pharm; 2018 Apr; 44(4):687-696. PubMed ID: 29168671
[TBL] [Abstract][Full Text] [Related]
13. Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability.
Du X; Gao N; Song X
Drug Deliv; 2021 Dec; 28(1):252-260. PubMed ID: 33501870
[TBL] [Abstract][Full Text] [Related]
14. Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers.
Murthy A; Ravi PR; Kathuria H; Malekar S
Nanomaterials (Basel); 2020 May; 10(6):. PubMed ID: 32486508
[TBL] [Abstract][Full Text] [Related]
15. Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene.
Alhakamy NA; Fahmy UA; Ahmed OAA
PLoS One; 2019; 14(12):e0226639. PubMed ID: 31881053
[TBL] [Abstract][Full Text] [Related]
16. Formulation and Characterization of Raloxifene Nanostructured Lipid Carriers for Permeability and Uptake Enhancement Applications.
Sharma A; Streets J; Bhatt P; Patel P; Sutariya V; Varghese Gupta S
Assay Drug Dev Technol; 2022; 20(4):164-174. PubMed ID: 35617693
[TBL] [Abstract][Full Text] [Related]
17. Preparation, characterization and in vitro evaluation of microemulsion of raloxifene hydrochloride.
Golmohammadzadeh S; Farhadian N; Biriaee A; Dehghani F; Khameneh B
Drug Dev Ind Pharm; 2017 Oct; 43(10):1619-1625. PubMed ID: 28489426
[TBL] [Abstract][Full Text] [Related]
18. Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment.
Soni NK; Sonali LJ; Singh A; Mangla B; Neupane YR; Kohli K
Nanotechnology; 2020 Nov; 31(47):475101. PubMed ID: 32886644
[TBL] [Abstract][Full Text] [Related]
19. Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells.
Fahmy UA; Badr-Eldin SM; Aldawsari HM; Alhakamy NA; Ahmed OAA; Radwan MF; Eid BG; Sayed SRM; El Sherbiny GA; Abualsunun W
Drug Deliv; 2022 Dec; 29(1):1863-1877. PubMed ID: 35708464
[TBL] [Abstract][Full Text] [Related]
20. Physically Optimized Nano-Lipid Carriers Augment Raloxifene and Vitamin D Oral Bioavailability in Healthy Humans for Management of Osteoporosis.
Hosny KM; Bahmdan RH; Alhakamy NA; Alfaleh MA; Ahmed OA; Elkomy MH
J Pharm Sci; 2020 Jul; 109(7):2145-2155. PubMed ID: 32194094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
